Archives: Speakers

Hannah currently leads J.P. Morgan Payments’ Marketing Campaign Strategy for the EMEA region. Equal parts strategist and creative, much of her time is spent thinking about the future of Payments, from the perspective of end users, merchants, and processors, and conveying that in a digestible format for all audiences, regardless of their Payments acumen. Passionate about Gender equity, Hannah Co-Chaired the Gender Network at Barclays, where she founded the Barclays Career Kickstarter, an initiative designed to dispel the misconception of an ‘ideal candidate’ in early careers. The scheme provides resources and advice to students, largely targeting those not yet considering a career in Financial Services, aiming to increase black, female and non-STEM graduate representation. At J.P. Morgan Payments, Hannah has remained passionate about early careers, currently leading the London Payments Apprenticeship programme. Dubbed One to Watch by Brummell Magazine, Hannah is part of a new generation of Payments professionals driving the next phase of change in our industry.

I am a M.Sc. graduate in life sciences and Bbiotechnology (the Hebrew University of Jerusalem, Israel). After graduating’ I have acquired vast experience in the biomed industry and research and development of innovative botanical products. For the past six years, I have served as R&D, Quality and Vocational Training Director in the Israeli Ministry of Health’s Medical Cannabis Agency (IMCA). There, I took a major part in designing the policy and regulation for the emerging medical cannabis industry, including writing the clinical methodology and quality procedures for medical cannabis products. Currently, I am the Head of the Medical Cannabis Clinical Research Center at the Chaim Sheba Hospital, Tel Hashomer, Israel; and an academic coordinator of the “cannabis for medical and research” course in the School of Graduate Studies, Sackler Faculty of Medicine, Tel Aviv University.

Julio discovered he had Hepatitis C by chance in 1994. He went through three year-long courses on interferon treatment. These years were not easy and Julio struggled with many challenges and questions and he looked for support. When he realized there are no support groups or patient associations for liver patients in Israel, Julio decided in 1998 to establish Hetz- the Israeli Organization for Liver Health. Today Julio is cured from HCV. Nevertheless, he dedicates his life to supporting liver patients and their families, strengthening Hetz’s capacity to advocate for the PATIENTS’ RIGHT TO KNOW they have a liver disease, and the government’s obligation to screen and to treat them. Actually Julio is directing HETZ and is representative of the patients in the National Council of Liver of the Ministry of Health in Israel.

Yael Genosar, Associate Director of Clinical Supply Chain at OPKO Biologics Israel. Experienced Clinical Supply chain manager with four years of experience in managing supply chain in a global clinical trial. Previously Project Manager at Hot Mobile a wireless telecommunications company, leading technologies projects.

Ms. Xia currently holds the position of Head of Supply Chain at Agios Pharmaceutical located in Cambridge, Massachusetts. Her responsibility includes clinical supplies, commercial supplies, logistic/commercial distribution and supply chain planning. Wendy is a chemist by training and has spent her early years in Chemical Development as a process chemist and analytical chemist. She then spent 20 years in Quality and Supply Chain organizations in major pharmaceutical companies in New Jersey before relocating to Cambridge, Massachusetts joining Agios in 2014. In 7 years, Wendy has successfully built a complete supply chain organization supporting clinical and commercial portfolios.

Seasoned R&D Industry professional with over 30 years of experience in large pharma, mid-sized, start-up and virtual settings. Career appointments span the full spectrum of product life-cycle management, across every phase of development and every research platform, including pharmaceuticals, biologics, devices, combination products, gene and stem cell therapeutics, Phases I-IV. Achievements include contribution to the US and International market approval of 6 biopharmaceutical products.